Prostate Cancer

In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.

In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.

An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.

The PAIREDCAP trial looked at different biopsy approaches to see which has the highest cancer detection rate for prostate cancer.

A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for metastatic castration-resistant prostate cancer.

Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.

The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer.

Researchers tested the administration of bone-targeted agents once every 12 weeks vs once every 4 weeks for a year in patients with metastatic castration-resistant prostate cancer.

Researchers tested treatment with bone-protecting agents in men with metastatic castration-resistant prostate cancer treated with enzalutamide or radium-223.

The phase III ENZAMET study showed 'practice-changing' results with enzalutamide for men with metastatic hormone-sensitive prostate cancer.

The TOPARP-B study showed that olaparib had activity in patients with metastatic castration-resistant prostate cancer with DNA damage repair gene defects.

The researchers compared hormonotherapy plus radiotherapy vs radiotherapy alone in prostate cancer patients who previously underwent radical prostatectomy.

Researchers tested the androgen receptor inhibitor apalutamide plus ADT in patients with metastatic castration-sensitive prostate cancer.

This study compared combination therapy with enzalutamide, abiraterone, and prednisone vs enzalutamide alone in men with metastatic castration-resistant prostate cancer.

This study tested first-line treatment with cabazitaxel vs hormonal therapy in patients with metastatic castration-resistant prostate cancer with poor prognosis.

This case looks at an otherwise healthy 59-year-old man who was recently diagnosed with clinical stage IVB prostate adenocarcinoma. What is the most appropriate management for this patient?

Researchers looked at the use and effects of 5α-reductase inhibitors to treat benign prostatic hyperplasia on prostate cancer outcomes.

Final results of LATITUDE confirm the benefit of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer.

In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.

The researchers explored implementation of physical activity for men recently diagnosed with prostate cancer to see which interventions will be best sustained over time.

The clinic educates, evaluates, and guides patients with prostate cancer on available treatments and helps to control associated anxiety.

Telerehabilitation and pharmacological pain management approaches were tested in patients with advanced cancers, including prostate cancer, to see if pain and function could be improved.

Researchers tested the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in patients with localized high-risk prostate cancer.

Updated prostate cancer guidelines reflect the importance of tumor genetic testing and genomically-informed disease management.

Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.

A large Danish registry study looked at the effects of post-diagnosis use of low-dose aspirin on prostate cancer mortality.

Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer.

Researchers found that the HSD3B1 genotype may be a predictive biomarker for the use of certain prostate cancer therapies.

The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium.

The results of the double-blind, phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.